Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial
Authors:
- 19 September 2011
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 28 (10) , 1176-1181
Abstract
Patients with Type 1 diabetes have significantly elevated postprandial glucagon secretion. Dipeptidyl peptidase IV inhibitors improve HbA(1c) by several mechanisms, including increasing glucagon-like peptide 1 and glucose-dependent insulinotropic peptide concentrations, which decreases postprandial rises in glucagon in both Type 1 and Type 2 diabetes. This study evaluates the clinical implications of sitagliptin in adult patients with Type 1 diabetes. This investigator-initiated, double-blind, randomized, crossover, 8-week, pilot study enrolled 20 adult subjects with Type 1 diabetes. Subjects received sitagliptin 100 mg/day or placebo for 4 weeks and then crossed over. Outcomes included 2-h postprandial blood glucose and 24-h area under the curve changes in glucose measurements from continuous glucose monitoring, HbA(1c) , fructosamine and insulin dose. Sitagliptin significantly reduced blood glucose (2-h postprandial and 24-h area under the curve) despite reduced total and prandial insulin dose. Based on continuous glucose monitor findings, sitagliptin improved measures of glycaemic control, including mean blood glucose (-0.6 mmol/l; P = 0.012) and time in euglycaemic range 4.4-7.8 mmol/l (0.4 ± 0.2 h; P = 0.046). Significant reductions were also observed in M100, Glycemic Risk Assessment Diabetes Equation (GRADE) and J-index. After controlling for period, treatment and insulin dose, the HbA(1c) was also significantly reduced [-0.27 ± 0.11% (-2.91 ± 1.16 mmol/mol); P = 0.025] when patients were taking sitagliptin. Sitagliptin significantly improved overall glucose control, including postprandial and 24-h glucose control, in adult patients with Type 1 diabetes, while significantly reducing prandial insulin requirements. Further investigation is warranted in patients with Type 1 diabetes in a larger cohort designed to assess both clinical outcomes and mechanism of action.Keywords
This publication has 15 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Increasing Incidence of Type 1 Diabetes in 0- to 17-Year-Old Colorado YouthDiabetes Care, 2007
- Relationship of Fasting and Hourly Blood Glucose Levels to HbA1c ValuesDiabetes Care, 2006
- Paradoxical Stimulation of Glucagon Secretion by High Glucose ConcentrationsDiabetes, 2006
- Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 DiabetesNew England Journal of Medicine, 2005
- Psychosocial problems and barriers to improved diabetes management: results of the Cross‐National Diabetes Attitudes, Wishes and Needs (DAWN) StudyDiabetic Medicine, 2005
- Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes MellitusThe Journal of Clinical Endocrinology & Metabolism, 2003
- Contributions of Fasting and Postprandial Plasma Glucose Increments to the Overall Diurnal Hyperglycemia of Type 2 Diabetic PatientsDiabetes Care, 2003
- Retinopathy and Nephropathy in Patients with Type 1 Diabetes Four Years after a Trial of Intensive TherapyNew England Journal of Medicine, 2000
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993